This study evaluates the efficacy of fitusiran, an investigational RNA interference (RNAi) therapeutic, in reducing bleeding episodes in a mouse model deficient in coagulation Factor X. The research aims to determine whether fitusiran can restore hemostasis in the context of Factor X deficiency by targeting antithrombin to rebalance coagulation pathways.
Administration of fitusiran led to a significant reduction in bleeding events in Factor X-deficient mice, indicating that lowering antithrombin levels can compensate for the lack of Factor X and restore hemostatic balance.
The study utilized a Factor X-deficient mouse model developed in collaboration with genOway. This model carries a targeted deletion of the F10 gene, resulting in a severe bleeding phenotype that mimics human Factor X deficiency.
Hemophilia, Coagulation disorders, RNA interference therapy, Antithrombin modulation, Bleeding management
Gene Knockout, Hemostatic assessment, RNAi therapeutic evaluation, Coagulation factor deficiency model, Antithrombin targeting
From model design to experimental results
Featured in 600+ scientific articles
Collaboration with 17 Top Pharmas,
170+ Biotechs and 380+ Academic Institutions
Generated with biopharma partners and in-house
and guaranteed freedom to operate
Models with certified health status from professional breeders in US and Europe
